Abstract
Background and Aim: A double-blind, randomized phase III trial of sorafenib in advanced hepatocellular carcinoma demonstrated that sorafenib significantly prolonged overall survival compared to placebo (median overall survival=10.7 months vs 7.9 months, P
Original language | English |
---|---|
Pages (from-to) | 1739-1746 |
Number of pages | 8 |
Journal | Journal of Gastroenterology and Hepatology |
Volume | 25 |
Issue number | 11 |
DOIs | |
Publication status | Published - 2010 |
Keywords
- Cost-effectiveness
- Economic models
- Hepatocellular carcinoma
- Sorafenib
ASJC Scopus subject areas
- Gastroenterology
- Hepatology